Proventa International will be gathering over 100 C-Level Directors from a mix of emerging to large Pharmaceutical, Biotechnology & Academic/Research Institutions to help solve their key strategic challenges in the area of Oncology.Register Now
The Oncology Roundtable Discussions Strategy Meeting are for qualified end-users. These include Senior Executives of Oncology/Immuno-Oncology (from medium to large Pharma, Biopharma and Biotech players) in global development positions spanning early development to phase IV, as well as thought leaders from Academia and regulatory authorities.
Thought leaders who will benefit from attending include CXOs, EVPs, SVPs, VPs, Executive Directors, Directors and Global Heads responsible for:
– Oncology R&D,Translational Research/Development/Medicine, Clinical Research/Development, Immuno-Oncology, Medical Affairs Oncology,Clinical Pharmacology,Oncology Clinical Biostatistics and Programming, Oncology Clinical Genomics and Computational Biology, Oncology R&D Innovation, Oncology R&D Strategy, Oncology Portfolio/Project Management.
Those who do not qualify for VIP passes, including vendors, exchanges, consultancies and other service providers, can apply here.
President and Chief Executive Officer, Tracon Pharmaceuticals
Dr. Theuer joined TRACON as President, Chief Executive Officer, and a board member in July 2006. From 2004 to 2006, Dr. Theuer was Chief Medical Officer and Vice President of Clinical Development at TargeGen, Inc. where he led the development of small molecule kinase inhibitors in oncology, ophthalmology and cardiovascular disease. Dr. Theuer was the Director of Clinical Oncology at Pfizer, where he led the clinical development of Sutent® in kidney cancer; Sutent® was approved by the U.S. Food and Drug Administration in 2006 for the treatment of advanced kidney cancer. Dr. Theuer has also held senior positions at IDEC Pharmaceuticals and the National Cancer Institute where he was involved in the development of multiple small molecules and monoclonal antibody therapies. Dr. Theuer holds a B.S. from MIT, an M.D. from UC San Francisco, and a Ph.D. from UC Irvine. He completed a general surgery residency program at Harbor-UCLA Medical Center. Dr. Theuer has held academic positions at the National Cancer Institute and at the University of California, Irvine, where he was a member of the Division of Surgical Oncology. His previous research involved immunotoxin and cancer vaccine development, translational work in cancer patients, and gastrointestinal cancer epidemiology.
Senior Vice President and Head of Product Supply Biotech, Bayer Pharmaceuticals
With more than 20 years of industry experience in biomanufacturing and drug development, Dr. Judy Chou currently heads the global Pharmaceutical Product SupplyBiotech organization overseeing the manufacturing and distribution of Bayer’s $3 billion biotechnology product portfolio. In addition, she serves as the site head for Bayer’s facility in Berkeley, CA, USA.
Before Bayer, she held the role of Vice President of Pharmaceutical/Technical Operations at Pfizer, Inc., formerly Medivation, where she led the Development and Manufacturing organizations for both biologics and small molecule products. She was also Vice President of R&D at Tanvex Biopharma, Inc., where Dr. Chou led the development of rich pipeline projects and provided leadership in R&D, manufacturing, preclinical and clinical functions to enable the success of the company’s IPO. Throughout Dr. Chou’s career, she has achieved significant milestones in protein therapeutic development and multiple filings of BLAs and INDs of novel products. She is recognized for her work at Genentech, Wyeth Biopharma/Pfizer and Abbott Bioresearch/AbbVie, and has contributed to the development of breakthrough technologies in analytical characterization and the accelerated process and formulation development.
Before joining the industry, Dr. Chou was also a research faculty member at Harvard University Medical School, focused on cell biology and neuroscience research. Dr. Chou obtained her Ph.D. from Yale University and completed her post-doctoral training at Max-Planck Institute in Germany.
Senior Vice President, Development Sciences & Regulatory Affairs, Teneobio, Inc
Dr. Iyer has over 20 years of experience in the biotech industry that spans drug discovery, translational research, regulatory interactions and clinical development. Prior to joining Teneobio in April 2017, Dr. Iyer was at Abbvie as Global Project Leader in Oncology Clinical Development where she led programs in early development. Prior to Abbvie, Dr. Iyer was at Genentech for 11 years during which she participated in and led preclinical and clinical development teams in immunology and oncology, resulting in key development milestones for several programs. She began her R&D career at Sangstat Medical Corp with over 9 years in discovery and early development research. She earned her Ph.D. from University of California at Davis, is a co-author on over 40 publications, has presented at numerous national and international forums and is a co-inventor on 5 patents.
Senior Vice President, Biometrics, Health Economics and
outcome Research, CTI BioPharma
Lixia Wang is Senior Vice President of CTI Biopharma Corp. She is responsible for managing Biometrics, Health Economic and Outcome Research in supporting drug development and commercialized. With 24 years’ experience working cross big pharma, and biotech companies, Lixia has increasing responsibilities held multiple leadership positions and successfully supported many products worldwide registrations and reimbursements. Lixia is passionate to use innovation to bring technology, data science to expedite and improve drug development. Lixia received his Ph.D. in Biostatistics from School of Public Health, University of South Carolina, had Master in Applied Statistics and Bachelor of Electronic and Computer Engineering.
Vice President, Diagnostics, Ignyta
Jason Christiansen is the Vice President of Diagnostics for Ignyta. His teams drive the companion diagnostic strategies, test development and applications to support Ignyta’s various therapeutic pipelines. This includes testing in Ignyta’s CLIA/QSR laboratory or working to collaborate and develop different platforms among the clinical trial sites. Prior to Ignyta, Dr. Christiansen was Sr. Director of Assay Development at Genoptix/Novartis, bringing multiple testing platforms, including NGS and digital pathology, into clinical use. Earlier, he led operations and diagnostic development efforts at other biotechnology companies (i.e., HistoRx, Protedyne, Molecular Staging). He received his PhD in Biophysics from the University of California.
President & Chief Medical Officer
Kwoya Kirin Pharmaceutical Development Inc.
Jeffrey Humphrey is an oncologist, Chief Medical Officer and President of Kyowa Kirin Pharmaceutical Development Inc. (KKD) based in Princeton, New Jersey. KKD is the American/European drug development subsidiary of Kyowa Hakko Kirin Company (KHK), a top-50 pharmaceutical company aspiring to become a Global Specialty Pharmaceutical company. As CMO/President, Jeff has oversight for US and European development of experimental therapeutics for oncology, neurology, immunology, and a rare genetic disorder. KKD is developing 2 first-in- class KHK compounds that are approved in Japan for T-cell Leukemia and Parkinson’s disease, respectively. Dr.Humphrey is the first American president of KKD, a member of KHK’s senior R&D decision-making committee, and a member of the CEO’s executive committee.
Dr. Humphrey previously served as VP of Oncology at both Bristol-Myers Squibb and Bayer Pharmaceuticals, and Clinical Exploratory Head of Oncology at Pfizer. Dr. Humphrey’s work over the past 20 years has included oversight or direct involvement in development of experimental and marketed oncology medicines, including submissions and/or launches of Sprycel, Ixempra, Yervoy, Erbitux, Nexavar, Ftorafur, and Taxol. He has developed specialized knowledge in anti-angiogenesis, companion diagnostics, and immuno-oncology during his career.
Dr. Humphrey holds an A.B., cum laude, from Harvard University in applied mathematics, anMD, Alpha Omega Alpha, from Case Western University School of Medicine, and completed his internal medicine internship and residency at the Johns Hopkins Hospital. Dr. Humphrey served as chief oncology fellow at the US NIH National Cancer Institute where he published original research in cell biology, biochemistry and molecular biology while completing fellowships in human medical genetics and medical oncology. Dr. Humphrey has co-authored multiple peer-reviewed publications, book chapters, and a patent, and has served as invited chairman and presenter at numerous academic and industry conferences.
Research & Development, MedImmune
Dr. Dixit conducted extensive graduate and post-graduate training in Toxicology–Biochemistry with both Indian and US Institutions (Case Western Reserve University, Medical College of Ohio, University of Nebraska) and is board certified in Toxicology from the American Board of Toxicology, Inc. since 1992. Rakesh served as a Senior Toxicologist with Midwest Research Institute between 1987 and 1992.
In December 1992, Rakesh joined the Department of Safety Assessment, Merck and Co., Inc, West Point, PA where he served in various management positions. During his about 14 years with Merck, Rakesh contributed to the successful filings of many blockbuster drugs. For about a year, Rakesh was associated with Johnson and Johnson PRD, La Jolla/Alza as Senior Director of Toxicology.
In Aug 2006, Rakesh joined MedImmune, Inc. (an AstraZeneca Biologics company) as Senior Director (R &D) & Global Head of Biologics Safety Assessment, Experimental Pathology, and Laboratory Animal Medicine. In his current position as a Vice President of R &D since 2010, Rakesh is responsible for providing guidance on research and development of biological products; including nonclinical toxicology/safety support for all AstraZeneca-MedImmune biologics products, including monoclonal antibodies and vaccines. Rakesh has published more than 60 papers in renowned international journals and has given over 100 invited lectures/presentations/workshops in national and international meetings. Rakesh is one of the most invited speakers in the biotechnology industry.
Rakesh’s areas of expertise are mainly in the area of pharmaceuticals and biologics drug development, safety assessment of small molecule drugs, biologics, vaccines and in exploring mechanisms of toxicity and biologics pharmacological activity. Rakesh has helped to bring several blockbuster pharmaceuticals to the market while working at Merck. Rakesh a recognized expert in safety and pharmacology biomarkers and their applications.. Rakesh is the Editor-in- chief of Toxicology Mechanisms and Methods and Associate Editor for Toxicology Applied Pharmacology, and Journal of Toxicology and Environmental Health. Rakesh was selected by his pharmaceutical peers as the 100 Most Inspiring People in Pharmaceutical Industry by PharmaVOICE in 2015. Rakesh also serves as an expert reviewer and in appointed committee for many programs managed by the prestigious U.S. National Academy of Sciences and US National Institutes of Health, including National Cancer Institute.
Hyatt Regency San Francisco Airport
1333 Bayshore Highway, Burlingame, California, 94010